From the pharmacy of the world to your tender desk.
M Care is an Indian-owned pharmaceutical export house supplying WHO-GMP and EU-GMP medicines, biologicals and surgical consumables to hospitals, importers and government tender desks across the United Kingdom, the GCC, and Africa, with destination-ready dossiers, validated cold-chain, and a single named account manager on every shipment.
Rooted in the world's pharmacy
India supplies ~60% of the world's vaccines and the largest share of quality-assured generics outside the US. That is the manufacturing base we buy against, then QA, dossier and ship on your behalf.
Regulator-ready, destination-first
CTD/eCTD dossiers written for MHRA, EMA, SFDA, MoH-UAE, NAFDAC and the rest of the regulators we ship into, not a generic template repurposed page-by-page.
One named person on every order
No call-centre triage, no vanishing reply chains. Your Mumbai desk knows your molecule, your market, your pack-size preference and your customs broker by name.
Four services. One operational backbone.
Sourcing, regulatory affairs, cold-chain logistics and post-shipment aftercare run through the same team in Mumbai, so the number on day-one's quote is the number on day-forty's invoice.
Pharmaceutical exports
Oncology, anti-infectives, cardiovascular, CNS and chronic-therapy portfolios from WHO-GMP and EU-GMP sites, against hospital, retail and tender orders.
How it works →Cold-chain & biologicals
Vaccines, insulins, monoclonal antibodies, blood-derived products. Validated 2–8°C and −25°C lanes. Live temperature telemetry. Independent QP release where required.
Cold-chain protocol →Unlicensed & named-patient
MHRA Specials, end-of-lifecycle molecules, compassionate-use supply under MHRA, EMA, SFDA and GHC frameworks. Turnaround measured in days, not weeks.
Named-patient supply →Hospital & tender supply
Single-source tender responses with full artwork compliance, in-country registration certificates, batch-level documentation and OTIF shipment discipline.
Tender capabilities →From Mumbai, into twelve regulated and emerging markets.
Direct export lanes from our Mumbai dispatch hub to hospitals, importers and tender desks across the UK, the GCC and Africa, with selective supply into Germany. Every lane is temperature-validated where biologics demand it and documented for the destination regulator.
Built for the contract, not the click.
Pharmaceutical exports don't win or lose on the price column. They win on whether the regulator accepts the dossier, whether the 2–8°C lane held from Mumbai to Mombasa, and whether the invoice, certificate of analysis and pack insert line up, down to the comma, when customs opens the carton.
That is the work nobody sees. It is also the only work that matters. We have built the business around it: direct relationships with WHO-GMP and EU-GMP manufacturers, in-house regulatory affairs, audited logistics partners, and the kind of documentation discipline that turns "maybe next quarter" into "cleared, released, delivered."
- Direct relationships with 80+ WHO-GMP manufacturing sites, no brokered stock, no batch mysteries.
- In-house regulatory affairs: dossier authoring, variations, renewals, destination-regulator liaison.
- Artwork control: destination-market labelling and leaflets prepared before shipment, not after rejection.
- Insurance priced into the unit rate, no claim-time surprises.
Depth where you need it. Breadth where you don't.
The portfolio is built around the disease areas that fill hospital pharmacies and tender desks, oncology, anti-infectives, cardiovascular, CNS, diabetes and critical care. Each area is deep: multiple molecules, multiple strengths, multiple dosage forms, each line traceable to a named manufacturing site.
We also stock the things the catalogue pages rarely mention: cold-chain biologicals, intensive-care paralytics, surgical consumables and the hard-to-source named-patient specials that keep a hospital pharmacy working when the primary supplier has defaulted.
Proof written in shipments, not slogans.
Ten years of export operations from Mumbai to twenty markets. The figures below are drawn from our 2025 operational log and audited quality records.
20 export markets served across the UK, European Union, GCC, East and West Africa and ASEAN — every market on a documented regulatory pathway, every shipment on a country-specific dossier.
18 therapeutic categories, 10,000+ SKUs on panel, with 42+ WHO-GMP and EU-GMP manufacturing partners audited and shortlisted against the MHRA, SFDA, MOHAP, NAFDAC and PPB quality frameworks.
One-working-day written quote on every enquiry, with price, availability and regulatory status for the destination country. Three in-market offices — Mumbai, London, Dubai — so the clock never gets in the way of an answer.
Tell us which molecule, which market, which volume.
One working day to a written reply with price, availability and regulatory status for your destination. No call-centre triage. No sales funnel. Just a human in Mumbai with the answer.
Request a quote → Browse portfolio